Breaking News, Trials & Filings

FDA Approves FluMist for Young Children

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MedImmune, Inc. received approval from the FDA for the expanded use of FluMist (Influenza Virus Vaccine Live, Intranasal) in children two to five years of age. FluMist is now approved for active immunization for the prevention of influenza A and B viruses in individuals two to 49 years of age. The company expects to ship FluMist with the expanded label in the next few days. FluMist is different from the flu shot in that it uses live, attenuated — or weakened — viruses within the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters